Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Spineguard S.A. is a pioneering company in the medical technology sector, specializing in the development of advanced surgical tools aimed at enhancing the safety and efficiency of spinal surgery. The company's flagship innovation is the Dynamic Surgical Guidance (DSG) technology, which provides real-time feedback during spinal implant placement. This technology is designed to reduce surgical complications and improve patient outcomes by offering precise navigation capabilities during operations. Spineguard S.A. primarily targets healthcare professionals and institutions, including hospitals and specialist clinics focused on orthopedics and neurosurgery. By improving the accuracy and safety of spinal procedures, the company's products are critical in reducing the risk of surgical errors, thereby having a significant impact on patient care and recovery. In the broader medical device market, Spineguard S.A. stands out for its commitment to integrating cutting-edge technology with practical surgical applications. This focus not only supports the evolving needs of the healthcare industry but also contributes to the advancement of surgical standards globally. Established in 2009, Spineguard is headquartered in France and continues to innovate in the field of surgical tools.
The business is unprofitable at the operating level (-44.19% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 19.2% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -€1M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€4M
▼ -19.2% YoY
Net Income (TTM)
-€2M
▲ +32.9% YoY
Op. Margin
-44.19%
▲ +21.7pp YoY
ROIC
-19.66%
▲ +11.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€1M
▲ +57.4% YoY
Op. Cash Flow (TTM)
-€1M
▲ +57.7% YoY
Net Debt
-€265K
Net Cash Position
Cash & Equiv.
€2M
3Y CAGR: -12.5%
Continue Research